{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Unjha Formulations Ltd
Why is Unjha Formulations Ltd falling/rising?
On 29-Apr, Unjha Formulations Ltd witnessed a notable recovery in its share price, rising by 5.52% to close at ₹22.00 after three consecutive days of decline. This rebound comes despite an initial gap down at the market open, reflecting a volatile trading session marked by heightened investor interest and mixed technical signals.
Markets Rally, But Unjha Formulations Ltd Sinks to 52-Week Low in Stock-Specific Sell-Off
Unjha Formulations Ltd’s stock price declined sharply on 7 April 2026, hitting a new 52-week low of Rs.18.6. This marks a significant downturn for the pharmaceutical and biotechnology company, reflecting ongoing challenges in its market performance and valuation metrics.
Markets Rally, But Unjha Formulations Ltd Sinks to 52-Week Low in Stock-Specific Sell-Off
Unjha Formulations Ltd’s stock price declined to a fresh 52-week low of Rs.18.99 on 2 April 2026, marking a significant drop amid broader market weakness and sectoral pressures. The stock has been underperforming, reflecting a combination of company-specific factors and challenging market conditions.
Markets Rally, But Unjha Formulations Ltd Sinks to 52-Week Low in Stock-Specific Sell-Off
A sharp decline of 9.31% today dragged Unjha Formulations Ltd to a fresh 52-week low of Rs 19, marking a significant underperformance against both its sector and the broader market. This drop comes amid a broader market sell-off, yet the stock’s fall notably outpaces the sector’s 3.63% decline and the Sensex’s 2.46% fall, highlighting company-specific pressures.
Unjha Formulations Ltd Falls to 52-Week Low of Rs.19.15 Amidst Continued Downtrend
Unjha Formulations Ltd’s shares declined to a fresh 52-week low of Rs.19.15 today, marking a significant milestone in the stock’s ongoing downward trajectory. The pharmaceutical company’s stock has underperformed both its sector and broader market indices, reflecting persistent concerns over its financial metrics and market positioning.
Unjha Formulations Gains 4.32%: Margin Pressures and Flat Growth Shape the Week
Unjha Formulations Ltd closed the week ending 6 February 2026 with a 4.32% gain, outperforming the Sensex’s 1.51% rise over the same period. Despite this positive price movement, the company reported flat quarterly financial performance amid margin compression, reflecting ongoing challenges in sustaining growth. The week was marked by a steady upward trend in the stock price, supported by moderate volumes and mixed market sentiment.
Unjha Formulations Ltd Reports Flat Quarterly Performance Amid Margin Pressures
Unjha Formulations Ltd, a player in the Pharmaceuticals & Biotechnology sector, has reported a flat financial performance for the quarter ended December 2025, signalling a notable shift from its previously positive growth trajectory. Despite a modest increase in profit after tax (PAT) over the last six months, the company’s overall financial trend score has deteriorated sharply, prompting a downgrade in its Mojo Grade to Strong Sell.
Are Unjha Formulations Ltd latest results good or bad?
Unjha Formulations Ltd's latest results show mixed performance; while net sales increased by 17.29% year-on-year to ₹4.41 crores, net profit plummeted by 70.73% quarter-on-quarter to ₹0.24 crores, indicating significant operational challenges and margin compression. Despite a strong return on equity of 32.48%, the company's profitability issues raise concerns about its operational efficiency and growth potential.
Unjha Formulations Q3 FY26: Profitability Plunges Amid Margin Compression
Unjha Formulations Ltd., a Gujarat-based pharmaceutical company specialising in Ayurvedic and Isabgol (Psyllium) formulations, reported a concerning quarter in Q3 FY26, with net profit plummeting 70.73% quarter-on-quarter to ₹0.24 crores from ₹0.82 crores in Q2 FY26. Despite modest revenue growth of 2.80% QoQ, the company's profitability came under severe pressure from margin compression.
When is the next results date for Unjha Formulations Ltd?
Unjha Formulations Ltd will announce its results on 04 February 2026.
Unjha Formulations Ltd Upgraded to Hold as Technicals Improve Amid Mixed Financials
Unjha Formulations Ltd has seen its investment rating upgraded from Sell to Hold as of 29 December 2025, reflecting a nuanced improvement across technical indicators, valuation metrics, and recent financial performance. Despite lingering challenges in long-term fundamentals and market underperformance, the company’s evolving technical trend and attractive valuation have prompted a reassessment of its outlook within the Pharmaceuticals & Biotechnology sector.
Unjha Formulations Ltd is Rated Sell
Unjha Formulations Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 23 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 24 December 2025, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market performance.
Unjha Formulations Sees Shift in Market Assessment Amid Mixed Financial and Technical Signals
Unjha Formulations, a player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in market assessment driven by a combination of technical trends, valuation metrics, financial performance, and broader market returns. This article analyses the key factors influencing the recent revision in the company’s evaluation, providing investors with a comprehensive understanding of the current landscape.
How has been the historical performance of Unjha Formul.?
Unjha Formul's historical performance has shown fluctuations in net sales and profits, with net sales decreasing to 13.86 Cr in March 2025 from 18.50 Cr in March 2024, but profit after tax increased to 0.41 Cr. Despite volatility, the company improved its profitability metrics and shareholder equity during this period.
Why is Unjha Formul. falling/rising?
As of 19-Nov, Unjha Formulations Ltd is priced at 26.40, with a recent short-term performance showing a 6.02% return over one week and 9.91% over one month, significantly outperforming the Sensex. However, a sharp decline in delivery volume raises concerns about the sustainability of this price increase, and the stock has a year-to-date decline of 13.13%.
Why is Unjha Formul. falling/rising?
As of 13-Nov, Unjha Formulations Ltd's stock price has risen to Rs 26.99, reflecting an 8.39% increase, and has outperformed its sector significantly. Despite a recent decline in investor participation, the stock shows strong long-term growth potential with a 166.70% increase over three years.
Unjha Formulations Reports Strong Financial Performance Amid Market Volatility
Unjha Formulations has reported strong financial performance for the quarter ending September 2025, achieving record figures in key metrics such as PBDIT, PBT, and PAT. The company's stock has shown volatility, with notable fluctuations in price, while long-term returns have significantly outperformed the Sensex.
Unjha Formulations Q2 FY26: Micro-Cap Pharma Posts Highest Quarterly Profit Despite Valuation Concerns
Unjha Formulations Ltd., a Gujarat-based micro-cap pharmaceutical company specialising in Isabgol (Psyllium) formulations, reported its highest-ever quarterly net profit of ₹0.82 crores in Q2 FY26, marking a substantial turnaround from previous quarters. The company's net profit surged 110.26% quarter-on-quarter (QoQ) and reversed from a loss of ₹0.11 crores in Q2 FY25, representing a year-on-year (YoY) swing into profitability. However, despite these improved operational metrics, the stock trades at a "Very Expensive" valuation with a market capitalisation of just ₹11.00 crores, raising questions about sustainability and investor expectations.
Is Unjha Formul. overvalued or undervalued?
As of November 12, 2025, Unjha Formul. is considered undervalued with a PE ratio of 11.08 and a PEG ratio of 0.40, significantly outperforming peers like Sun Pharma. and Divi's Lab., and demonstrating strong long-term returns of 149.21% over three years and 250.28% over five years, despite recent underperformance year-to-date.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
